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Monosodium Urate Monohydrate Crystal Deposits Are Common in Asymptomatic
Sons of Patients With Gout: The Sons of Gout Study
Abhishek Abhishek,1 Philip Courtney,2 Wendy Jenkins,1 Gabriela Sandoval-Plata,1 Adrian C. Jones,2 Weiya Zhang,1
and Michael Doherty1
Objective. To estimate the prevalence and distri-
bution of asymptomatic monosodium urate monohydrate
(MSU) crystal deposition in sons of patients with gout.
Methods. Patients with gout were mailed an
explanatory letter with an enclosed postage-paid study
packet to mail to their son(s) age ≥20 years old. Sons inter-
ested in participating returned a reply form and under-
went telephone screening. Subsequently, they attended a
study visit at which blood and urine samples were obtained
and musculoskeletal ultrasonography was performed, with
the sonographer blinded with regard to the subject’s
serum urate level. Images were assessed for double con-
tour sign, intraarticular or intratendinous aggregates/
tophi, effusion, and power Doppler signal. Logistic regres-
sion was used to examine associations. Adjusted odds
ratios (ORadj) and 95% confidence intervals (95% CIs)
were calculated.
Results. One hundred thirty-one sons (mean age
43.8 years, mean body mass index 27.1 kg/m2) completed
assessments. The serum urate level was ≥6 mg/dl in 64.1%,
and 29.8% had either a double contour sign or intraarticu-
lar aggregates/tophi in ≥1 joint. All participants with MSU
deposition had involvement of 1 or both first metatar-
sophalangeal joints. Intratendinous aggregates were pre-
sent in 21.4% and were associated with intraarticular
MSU crystal deposits (ORadj 2.96 [95% CI 1.17–7.49]). No
participant with a serum urate level of ≤5 mg/dl had MSU
crystal deposition seen on ultrasonography, and 24.2% of
those with serum urate levels between 5 and 6 mg/dl had
ultrasonographic MSU deposition. MSU crystal deposition
was associated with increasing serum urate levels (ORadj
1.61 [95% CI 1.10–2.36] for each increase of 1 mg/dl).
Conclusion. Asymptomatic sons of patients with
gout frequently have hyperuricemia and MSU crystal
deposits. In this study MSU crystal deposits were present
in participants with serum urate levels of ≥5 mg/dl. Eval-
uation of subjects without a family history of gout is
needed to determine whether the threshold for MSU crys-
tal deposition is also lower in the general population.
Gout is the most common form of inflammatory
arthritis and results from persistent hyperuricemia that
causes intra- and periarticular monosodium urate mono-
hydrate (MSU) crystal deposition. It has multiple risk fac-
tors including genetic factors that act by modulating renal
uric acid excretion (1). The heritability of serum urate
and urinary uric acid excretion is estimated to be ~60%
and 60–87%, respectively (2), while the heritability of
gout is lower at 17.0% and 35.1% in Taiwanese women
and men, respectively (3), and was estimated to range
between 0% and 58% in a study from the US (1). As
14.5–25% of people with high serum urate levels have
asymptomatic MSU crystal deposition (4–6), studies that
use a symptomatic disease phenotype may underestimate
the heritability of MSU crystal deposition.
The prevalence of asymptomatic MSU crystal
deposition in people at high genetic risk of gout, e.g.,
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those with a parent who has gout, is not known. It has
implications for screening and primary prevention of
symptomatic gout and contrasts with rheumatoid arthritis,
in which familial risk and prevalence of autoantibodies in
first-degree relatives are well understood. Thus, we under-
took the present study to 1) examine the prevalence and
distribution of asymptomatic MSU crystal deposition
among sons of people with gout; 2) examine the associa-
tion between serum urate, age, and asymptomatic MSU
crystal deposition; and 3) explore whether parental age at
gout onset is associated with asymptomatic MSU crystal
deposition in sons.
PATIENTS AND METHODS
Study design, subject recruitment, and ethics approval.
This community-based cross-sectional study was approved by the
Nottingham NHS Research Ethics Committee 2 (Rec ref: 15/
EM/0316). People with self-reported physician-diagnosed gout
who had participated in previous surveys at Academic Rheuma-
tology, University of Nottingham and consented to future
research contact were mailed a letter informing them of the
present study and were asked to mail an enclosed study packet
to their sons age ≥20 years. Sons of patients with primary gout
who attended the rheumatology clinic at the Nottingham NHS
Treatment Centre were approached in a similar manner, and the
study was advertised on Facebook and once in a local newspa-
per. These advertisements were targeted at sons living in and
around Nottingham who have a parent with gout.
Sons who returned a reply form or contacted us in
response to the advertisements underwent a telephone screening
questionnaire to exclude those with gout (7). The screening
questionnaire included questions that form part of the 8-point
chronic gout diagnosis (CGD) scale (7). The CGD scale includes
current or past history of attack of acute arthritis, monoarthritis
or oligoarthritis, rapid progression of pain and swelling (<24
hours), podagra, erythema, unilateral tarsitis, tophi, and hyper-
uricemia (7). As serum urate was not measured at the screening
visit in this study, a history of hyperuricemia was substituted. Par-
ticipants scoring ≤3 on the CGD were invited for the study visit.
Study visit. Participants attended a study visit at which
data on demographic characteristics, lifestyle factors, comorbidi-
ties, and drug prescriptions were collected. Targeted muscu-
loskeletal assessment was performed, height, weight, and blood
pressure were measured, and random blood and second-void
early-morning urine samples were collected. Serum urate and
creatinine and urinary uric acid and creatinine were measured at
the clinical pathology laboratories of Nottingham University
Hospitals NHS Trust. Fractional excretion of uric acid (FEUA)
was calculated as ([urinary uric acid 9 serum creatinine]/[serum
urate 9 urinary creatinine]) 9 100% (8).
Table 1. Disease and demographic characteristics of the sons of patients with gout*
Total
Asymptomatic MSU crystal
deposition
Present
(n = 39)
Absent
(n = 92)
Age, mean  SD years 43.80  11.20 44.20  8.91 43.63  12.08
Age 20–29 years, no. (%) 20 (15.3) 3 17
Age 30–39 years, no. (%) 27 (20.6) 10 17
Age 40–49 years, no. (%) 40 (30.5) 15 25
Age 50–59 years, no. (%) 36 (27.5) 10 26
Age 60–69 years, no. (%) 8 (6.1) 1 7
Body mass index, mean  SD kg/m2 27.10  4.75 27.65  3.99 26.85  5.04
Current purine-rich alcohol consumption, no. (%) 97 (74.1) 31 (79.5) 66 (71.7)
Weekly purine-rich alcohol intake, median (IQR) units 10 (5–20) 10 (5–20) 10 (4–20)
Hypertension, no. (%) 12 (9.2)† 3 (7.7) 9 (9.8)
Hyperlipidemia, no. (%) 10 (7.6)‡ 3 (7.7) 7 (7.6)
Diabetes, no. (%) 2 (1.5)§ 0 2 (2.2)
eGFR, mean  SD ml/minute 85.23  7.19 85.21  7.71 85.24  7.00
Serum urate, mean  SD mg/dl 6.41  1.13 6.79  0.96¶ 6.25  1.16
Serum urate <5 mg/dl, no. (%) 14 (10.5) 0 14
Serum urate ≥5 and <6 mg/dl, no. (%) 33 (26.9) 8 25
Serum urate ≥6 and <7 mg/dl, no. (%) 46 (34.3) 18 28
Serum urate ≥7 and <8 mg/dl, no. (%) 27 (20.2) 8 19
Serum urate ≥8 and <9 mg/dl, no. (%) 9 (6.7) 4 5
Serum urate ≥9 mg/dl, no. (%) 2 (1.5) 1 1
FEUA, mean  SD % 5.3  1.9 5.3  1.7 5.3  1.9
Father with gout, no. (%) 111 (84.7) 33 (84.6) 78 (84.8)
* All participants with asymptomatic monosodium urate monohydrate (MSU) crystal deposition had first metatarsopha-
langeal joint involvement. IQR = interquartile range; eGFR = estimated glomerular filtration rate; FEUA = fractional excre-
tion of uric acid.
† Eleven participants were prescribed antihypertensive drugs; 1 received bendroflumethiazide.
‡ Six participants were prescribed statins.
§ Both participants were prescribed oral hypoglycemic drugs.
¶ P = 0.01 versus participants without asymptomatic MSU crystal deposition.
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Ultrasonography was performed by a rheumatologist
with 5 years of ultrasonography experience (AA), who was
blinded with regard to the subject’s serum urate level. The
ultrasonographic examination involved assessment of both
first metatarsophalangeal (MTP) joints, talar domes, femoral
condyles, second metacarpophalangeal joints, wrist triangular
fibrocartilages, and patellar and triceps tendon insertions (9).
These joints and tendons were chosen as they have best sensitiv-
ity and specificity for differentiating subjects with gout from
those with other arthropathies (9). Ultrasound images were
scored for double contour sign, intraarticular or intratendinous
tophi/aggregates, and hyperechoic deposits (present or absent,
as defined by the Outcome Measures in Rheumatology group
[10]). Joint effusion and power Doppler signal were graded on a
0–3 scale. All ultrasonographic assessments were performed
using a Toshiba Aplio machine (8–14 MHz). Images with incon-
clusive readings were reviewed by a second ultrasonographer
with >15 years of ultrasonography experience (PC), also under
blinded conditions with regard to the subject’s serum urate level.
For the purpose of this study, MSU crystal deposits were defined
as present if there was an intraarticular double contour sign
or tophi/aggregates. Hyperechoic deposits alone were not suffi-
cient to define MSU crystal deposits. When available, data on
sex of the parent with gout and age at onset of gout were
extracted from databases at Academic Rheumatology, Univer-
sity of Nottingham.
Statistical analysis. The mean  SD and the number
(%) were used to describe continuous and categorical data,
respectively. Independent-sample t-tests and chi-square tests
were used for univariate analysis; the Kruskal-Wallis test was
used if the data were nonparametric. Logistic regression was
used to examine the association between intraarticular MSU
crystal deposition at any joint in an individual and 1) serum
urate level, 2) FEUA, 3) age, and 4) intratendinous aggregates/
tophi at any tendon. The associations were adjusted for age
where required, body mass index (kg/m2), current purine-rich
alcohol consumption (yes/no), hypertension (yes/no), hyperlip-
idemia (yes/no), diabetes (yes/no), estimated glomerular filtra-
tion rate (ml/minute), and father with gout (yes/no). Adjusted
odds ratios (ORadj) and 95% confidence intervals (95% CIs)
were calculated. The individual was the unit of analysis. Statisti-
cal calculations were performed using Stata version 15. P values
less than 0.05 were considered significant.
RESULTS
One hundred thirty-four participants were recruited
into the study: 125 via postal survey (1,435 study packets
sent, 249 replies received), 6 from among sons of gout
patients attending Nottingham University Hospitals NHS
Trust, and 3 from advertisements. The 3 individuals
recruited from advertisements did not present for ultra-
sonographic assessment and were excluded from further
analysis. The serum urate level was ≥6 mg/dl in 64.1% of
the subjects and ≥7 mg/dl in 29.0%. Demographic
characteristics and comorbidities of the 131 participants
are summarized in Table 1. The mean  SD FEUA was
5.33  1.87%, and FEUA was low (defined as ≤6.6%) in
78.6% of the subjects with a serum urate level of ≥6 mg/dl.
MSU crystal deposition was found in 29.8% of the
subjects, with involvement of the first MTP joint (Fig-
ure 1) observed in all subjects in whom asymptomatic
MSU crystal deposition was present. MSU crystal deposi-
tion was not found in any participant with a serum urate
level of ≤5 mg/dl. Among the 262 first MTP joints exam-
ined, intraarticular aggregates were numerically more
common than double contour sign (Table 2). Only 1
Figure 1. Ultrasonographic evidence of asymptomatic monosodium urate monohydrate crystal deposition. Left, Double contour sign in the
first metatarsophalangeal joint. Middle, Intraarticular tophus in the dorsal recess, with a double contour sign. Right, Punctate intratendinous
hyperechoic deposits.
Table 2. Distribution of ultrasound features at different joints and
tendons (n = 262 joints or tendons)*
Asymptomatic MSU
deposition in
first MTP joints
Present
(n = 49)
Absent
(n = 213)
First MTP joints
Double contour sign 13 (5.0) – –
Tophi 27 (10.3) – –
Double contour sign and tophi 9 (3.4) – –
Grade ≥2 effusion 56 (21.4) 26 30
Patellar tendon
Hyperechoic deposits 19 (7.3) 11 8
Unilateral 13 7 6
Bilateral 3 2 1
Triceps tendon
Hyperechoic deposits 15 (5.7) 8 7
Unilateral 13 6 7
Bilateral 1 1 0
* One participant had a double contour sign at 1 ankle; triangular
fibrocartilage involvement was not observed in any participant. Values
are the number (%) of joints/tendons. MSU = monosodium urate
monohydrate; MTP = metatarsophalangeal.
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participant had a double contour sign at the ankle, and
MSU crystal deposits were not present at the other joints
examined. MSU crystal deposition at the first MTP joint
was associated with grade ≥2 effusion at the same joint
(ORadj 9.44 [95% CI 3.62–24.63], ORadj 5.44 [95% CI
1.57–18.82] for the right and left sides, respectively). The
power Doppler signal was grade ≥2 in only 1 first MTP
joint.
Hyperechoic aggregates were present in at least
1 tendon in 28 participants (21.4%). Sixteen partici-
pants (12.2%) had patellar tendon involvement, and 14
(10.7%) had triceps tendon involvement. Of the 28 par-
ticipants with hyperechoic aggregates in at least 1 ten-
don, 14 had asymptomatic MSU crystal deposition at 1
or both first MTP joints. The presence of MSU crystal
deposition at either first MTP joint was associated with
the presence of hyperechoic aggregates in at least 1
tendon (OR 3.12 [95% CI 1.31–7.42]). This association
was statistically significant after adjustment for covari-
ates (ORadj 2.96 [95% CI 1.17–7.49]).
Subjects with asymptomatic MSU crystal deposi-
tion had higher serum urate levels than those without
(mean difference 0.54 mg/dl [95% CI 0.12–0.96]). The
prevalence of asymptomatic MSU crystal deposition at
either first MTP joint increased from 0% to 24.2%,
39.1%, 29.6%, 44.4%, and 50%, respectively, in partici-
pants with serum urate levels of <5, 5–5.99, 6–6.99,
7–7.99, 8–8.99, and ≥9 mg/dl (Table 1). Other disease,
demographic, and laboratory parameters were compara-
ble between the 2 groups (Table 1). MSU crystal deposi-
tion was associated with increasing serum urate level
(OR 1.50 [95% CI 1.06–2.11], ORadj 1.61 [95% CI 1.10–
2.36] for each 1-mg/dl increase in serum urate). How-
ever, there was no association between MSU crystal
deposition and uric acid underexcretion status (FEUA
≤6.6%) (OR 0.71 [95% CI 0.29–1.71], ORadj 0.78 [95%
CI 0.31–1.98]).
Among the 117 participants with serum urate
levels of ≥5 mg/dl (the cutoff value above which MSU
crystal deposits were found in this study), the prevalence
of asymptomatic MSU crystal deposition was 33.33%, and
this increased numerically from ages in the 20s to the 40s
before stabilizing (see Supplementary Table 1, on the
Arthritis & Rheumatology web site at http://onlinelibrary.
wiley.com/doi/10.1002/art.40572/abstract). However, the
increase was not statistically significant, and participants
age >40 years were not significantly more likely to have
asymptomatic MSU crystal deposition than those ≤40
years of age (OR 1.32 [95% CI 0.59–2.95], ORadj 1.69
[95% CI 0.34–8.47]). There was no association between
hyperuricemia and tendon hyperechoic deposits, and, in
those with serum urate levels ≥5 mg/dl, there was no
association between increasing age and tendon hypere-
choic deposits (Supplementary Tables 2 and 3, on the
Arthritis & Rheumatology web site at http://onlinelibrary.
wiley.com/doi/10.1002/art.40572/abstract).
Self-reported data on age at onset of gout were
available for 60 parents. The median age at onset was
53 years. On univariate analysis, there was no associa-
tion between parental gout onset at or before 53 years
of age and asymptomatic MSU crystal deposition (with
parental gout onset after the age of 53 years as the ref-
erent) (OR 2.64 [95% CI 0.79–8.87]). However, this
approached significance after adjustment for covariates
(ORadj 4.14 [95% CI 0.88–19.46], P = 0.07).
DISCUSSION
This study demonstrates that the sons of patients
with gout have a higher prevalence of hyperuricemia
(11), uric acid underexcretion (8), and asymptomatic
MSU crystal deposition than observed in previous stud-
ies in which participants were preselected according to
their serum urate level (4–6). The results also raise the
possibility that MSU crystal deposition occurs initially
in the first MTP joints and in tendons before appearing
in other joints such as the ankle and the knee. How-
ever, this observation is limited by the cross-sectional
study design. It was surprising that 1 in 5 subjects with
serum urate levels between 5 and 6 mg/dl had ultra-
sonographic features of MSU crystal deposition at the
first MTP joints. This observation must be interpreted
with caution as it is based on a single serum urate mea-
surement, and it is possible that serum urate levels in
these participants were higher at a previous time. How-
ever, it raises the possibility that the threshold for MSU
crystal deposition in vivo may be lower than that esti-
mated from laboratory studies. This may be due to the
fact that the saturation point of urate reduces from 6.75
mg/dl at 37°C to between 4.5 and 6 mg/dl at 30–35°C,
the mean temperature of the human big toe in temper-
ate climates (12,13).
While MSU crystals were present in subjects with
serum urate levels of 5–6 mg/dl, we did not find ultra-
sonographic evidence of MSU crystal deposition in those
with levels below 5 mg/dl. This raises the possibility that
the target serum urate level for treat-to-target urate-
lowering therapy should be <5 mg/dl, at least in individu-
als who continue to have gout flares despite serum urate
levels between 5 and 6 mg/dl. However, further prospec-
tive studies are needed before such a strategy can be rec-
ommended. A lower-than-expected serum urate level in
sons of patients with gout might also be explained in part
by inherited tissue factors (either an increase in
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promoters or decrease in inhibitors) that enhance MSU
crystal deposition at relatively low serum urate levels.
The present findings suggest that MSU crystal
deposition begins early (in the third decade of life) and
becomes more prevalent with increasing age. The reduc-
tion in prevalence of MSU crystal deposition in subjects
older than 60 years could be due to the sampling for this
study, as people older than 60 years with MSU crystal
deposits are likely to have developed gout flares, which
would have excluded them from the study population.
We observed intratendinous hyperechoic deposits
in 35.9% of participants with MSU crystal deposits else-
where. This is consistent with previous reports of tendon
involvement in gout (14,15). As shown in Table 2, a sub-
stantial proportion of tendon hyperechoic deposits
occurred in subjects without ultrasonographic features of
MSU crystal deposition in the first MTP joints. Further
research, e.g., using dual-energy computed tomography,
is therefore needed to confirm the composition of these
tendinous deposits before their presence can be used to
imply MSU crystal deposition in the absence of a double
contour sign or intraarticular tophi in other joints.
Our results indicate that ultrasonographic evalu-
ation of both first MTP joints is sufficient to identify
all individuals with MSU crystal deposition. Thus, men
at a high risk of gout (e.g., those with a positive family
history) could undergo serum urate measurement and
ultrasonography of both first MTP joints to screen for
MSU crystal deposition. While ultrasonographic exami-
nation of multiple peripheral joints is time consuming,
assessment of both first MTP joints takes 10–15 min-
utes and may make it possible for asymptomatic MSU
crystal deposits to be diagnosed, in turn allowing con-
sideration of lifestyle changes to prevent development
of symptomatic gout and associated consequences.
Initiation of prophylactic pharmacologic urate-
lowering treatment at this early stage would be consid-
ered controversial given the absence of symptoms and
the possibility that in many people with asymptomatic
MSU crystal deposition, gout flares would not develop.
Such a screening strategy would require ultrasonogra-
phy of 3 individuals with a serum urate level of ≥5 mg/
dl to detect 1 person with asymptomatic MSU crystal
deposition. However, in the absence of prospective
studies evaluating the relationship between asymp-
tomatic MSU crystal deposition and symptomatic gout,
the benefit from such a strategy remains unproven. Our
data also suggest that parents with younger-onset gout
are more likely to pass on the trait to their sons,
although this association was not statistically significant
and requires further investigation in a study with a lar-
ger sample size.
There are several caveats to this study. First, the
response rate was low, and it is possible that patients
with severe, troublesome gout were more likely to pass
on the study packets to their sons, or that sons with life-
style risk factors were more likely to agree to participate.
This raises the possibility of selection and response bias.
However, the mean  SD age at gout onset in parents
of sons who participated and for whom data on the age
at gout onset were available (n = 60) was 52  13.65
years, and they reported a mean  SD of 1.33  2.10
gout flares in the 12-month period preceding their origi-
nal research visit. These parents also had a low comor-
bidity burden, with a median of 1 cardiovascular or renal
comorbidity (interquartile range 1–2). Second, we did
not perform joint aspiration to confirm the validity of
our findings. However, in subjects with hyperuricemia,
ultrasonographic changes have 100% sensitivity and 88%
specificity for MSU crystal deposition, compared to joint
aspiration (5). Finally, we measured serum urate only on
a single occasion.
In conclusion, the results of this study demonstrate
that asymptomatic sons of patients with gout frequently
have hyperuricemia and uric acid underexcretion, and
have a high prevalence of MSU crystal deposition. This
suggests that screening of such individuals and discussion
of early management, involving addressing modifiable risk
factors (overweight, obesity, high fructose intake, etc.) in
order to reduce their risk of developing symptomatic gout,
should be considered.
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